Sanofi Reports Results of Olipudase alfa in Two Studies for Acid Sphingomyelinase Deficiency in Adults and Pediatric Patients

 Sanofi Reports Results of Olipudase alfa in Two Studies for Acid Sphingomyelinase Deficiency in Adults and Pediatric Patients

Sanofi Reports Results of Olipudase alfa in Two Studies for Acid Sphingomyelinase Deficiency in Adults and Pediatric Patients

Shots:

  • The P-II/III study involves assessing olipudase alfa (up to 3mg/kg, IV, q2w) vs PBO in 36 adult patients with ASMD for 52wks. demonstrating reduction in spleen volume (39.5% vs 0.5%); reduction in SRS (8.0 vs 9.3)
  • The P-II study involves assessing of olipudase alfa (up to 3mg/kg, IV, q2w) in 20 pediatric patients aged <18yrs. across six countries for 64wks. demonstrating a 33% increment in predicted DLco in 9 patients who performed the test at baseline @52wks. and a 49% reduction in spleen volume assessed by MN
  • Olipudase alfa is an investigational enzyme replacement therapy designed to replace deficient/ defective ASM, allowing the breakdown of sphingomyelin with its expected global regulatory submission to be initiated in H2’21

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post